EarningsQ3 2026 Earnings Report
DE:41O Q3 2026 EPS Results
Actual EPS-€0.08
Consensus EPS-€0.07
Beat/MissMissed by -<€0.01
One Year Ago EPS-€0.38
DE:41O Q3 2026 Revenue Results
Actual Revenue€7.50K
Expected Revenue€833.36K
Beat/MissMissed by -€825.87K
YoY Revenue Growth-99.42%
Earnings Announcement Details
QuarterQ3 2026
Date08/14/2026
TimeBefore Open
Conference CallFriday, August 14, 2026
DE:41O Upcoming Earnings
Outlook Therapeutics's next earnings date is estimated for December 18, 2026, based on past reporting schedules.
Q3 2026 Earnings Call Audio
DE:41O Q3 2026 Earnings Call
0:00 / 0:00
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a largely positive tone based on a transformational FDA approval, strong registrational efficacy data, clear commercial planning and recent financing to fund the U.S. launch. However, material risks remain: competitive pricing pressure from biosimilars, European commercialization challenges, reimbursement and patient affordability concerns, reliance on a J‑code and near‑term liquidity that required a public offering. Management positions the company to execute a measured launch with conservative forecasts and contingency upside if compounded bevacizumab availability changes.Company Guidance
FDA Approval of LYTENAVA
FDA approved LYTENAVA as the only FDA‑approved ophthalmic formulation of bevacizumab for wet AMD in the U.S.; management calls this transformational and a foundation for U.S. commercialization.
Strong Registrational Trial Results (NORSE TWO)
NORSE TWO showed 41.7% of LYTENAVA patients gained ≥15 letters at month 11 vs 23.1% for ranibizumab, forming the basis of a strong label and clinical messaging.
Large Addressable U.S. Retina Market
Company cites U.S. anti‑VEGF retina market ≈$8.5 billion annually, ~3.6M off‑label repackaged bevacizumab injections in 2025 (including ~2.2M for wet AMD), supporting significant commercial potential.
Peak Sales Potential and Upside
Base case potential >$500 million in peak annual U.S. sales by 2030; management estimates an upside of just under $300 million if large‑scale disruption of compounded repackaged bevacizumab occurs.
Launch Pricing Positioning
Target WAC price expected to be below $500 per vial to be competitive with biosimilars while reflecting LYTENAVA's differentiated FDA‑approved profile.
Commercial Launch Preparations
Planned pre‑launch actions include applying for a permanent HCPCS code by end of Q3 and anticipating a permanent J‑code in April 2027; planned hires: ~30 customer‑facing reps and ~20 field reimbursement personnel to support buy‑and‑bill market.
Initial U.S. Revenue Guidance Following Launch
Management expects total net revenue in the first 12 months post‑U.S. launch of $50M–$75M, with Europe contributing ~10%–15%. Projected progressive ramp: ~10% of first‑year revenue in first 3 months, ~50% generated in the fourth quarter following launch.
European Progress and Unit Sales Growth
LYTENAVA is available in Germany, Austria and the U.K.; Netherlands reimbursement submission planned and launch expected early 2027; European unit sales rose 46% quarter‑over‑quarter (Q3 vs Q2 FY2026).
Improved Adjusted Loss and Financing Secured
Adjusted net loss for Q3 FY2026 decreased to $10.9M ($0.09 per share) from $15.8M ($0.44 per share) year‑ago (~31% reduction in adjusted loss). Cash and equivalents were $11.2M at June 30; subsequent public offering announced for $55M gross (≈$51.1M expected net proceeds) to support the U.S. launch.
DE:41O Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed